Glaxo's new HIV combo trounces Gilead's Atripla

GlaxoSmithKline's ambitious effort to make a comeback in the HIV field took another big step forward today. A new HIV combo therapy backed by GSK ($GSK), Pfizer ($PFE) and Shionogi bested the leading treatment for the virus in a head-to-head study, spurring some rave reviews from very bullish analysts. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.